



Since 1 April 2019, Cancer52 has received support from the organisations listed below. We are most grateful for this support. The table below shows details of the different levels of funding that were received.

Financial Year 2019/20

Organisation	Level of Support	Details of funding
• BMS	• £10,000	• Core Funding
• Clinigen	• £19,000	• Core Funding
• Janssen	• £12,000	• Core Funding
• Pfizer	• £39,150	• Project specific funding

Financial Year 2020/21

Covid-19 Specific Funding

Organisation	Level of Support	Details of funding
• Amgen	• £7,000	• Core Funding (Covid-19 specific)
• Gilead	• £7,000	• Core Funding (Covid-19 specific)
• GSK	• £9,700	• Project Funding (Covid-19 Specific)
• Janssen	• £12,000	• Core Funding (Covid-19 specific)
• Novartis	• £7,875	• Core Funding (Covid-19 specific)
• Pfizer	• £10,000	• Core Funding (Covid-19 specific)
• Roche	• £7,000	• Core Funding (Covid-19 specific)
• Takeda	• £10,000	• Core Funding (Covid-19 specific)

Other Funding

Organisation	Level of Support	Details of funding
• BMS	• £15,000	• Core Funding

Corporate Supporters Programme 2021

Organisation	Level of Support	Details of funding
• Abbvie	• £10,000	• Corporate Supporters Programme 2021
• Gilead	• £10,000	• Corporate Supporters Programme 2021
• Kyowa Kirin	• £10,000	• Corporate Supporters Programme 2021
• Merck	• £10,000	• Corporate Supporters Programme 2021
• Roche	• £6,666	• Corporate Supporters Programme 2021 (part year)
• Takeda	• £10,000	• Corporate Supporters Programme 2021

Other Funding

Organisation	Level of Support	Details of funding
• Janssen	• £9,000	• Core Funding